Jones Financial Companies Lllp Has $578,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...
JD Supra2d
First Circuit Decision Raises Bar on Anti-Kickback Statute-Premised Liability Under the False Claims Act
The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...
Life Sciences IP Review3d
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...
Regeneron's Injunction on Eylea Biosimilar Holds Up on Appeal
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Precision Medicine Online5d
Adverum Biotechnologies Kicks Off Registrational Trial for Wet AMD Gene Therapy
In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Finanznachrichten11d
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
About Regeneron in Hematology At Regeneron ... without limitation the patent litigation and other related proceedings relating to EYLEA ® (aflibercept) Injection), the ultimate outcome of any such ...
REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.
A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...
PharmiWeb12d
Global Retinal Biologics Market to Reach USD 41.92 Billion by 2028 at a 11.1% of CAGR
Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...
StockNews16d
3 Precision Medicine Stocks That Could Transform Healthcare
With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine industry is expected to witness significant growth and expansion. Hence, it ...